Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C6EW
|
|||
Former ID |
DNC006858
|
|||
Drug Name |
Ustiloxin F
|
|||
Synonyms |
Ustiloxin F
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C21H30N4O8
|
|||
Canonical SMILES |
CCC1(C(NC(=O)C(NC(=O)C(C(C2=CC(=C(C=C2)O)O1)O)NC)C)C(=O)NCC(=O)O)C
|
|||
InChI |
1S/C21H30N4O8/c1-5-21(3)17(20(32)23-9-14(27)28)25-18(30)10(2)24-19(31)15(22-4)16(29)11-6-7-12(26)13(8-11)33-21/h6-8,10,15-17,22,26,29H,5,9H2,1-4H3,(H,23,32)(H,24,31)(H,25,30)(H,27,28)/t10-,15-,16+,17+,21+/m0/s1
|
|||
InChIKey |
XAJYTGHEDODUTC-KILRJQPKSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin beta (TUBB) | Target Info | Inhibitor | [1] |
Tubulin beta-2 chain (TUBB2) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Phagosome | |||
Gap junction | ||||
Pathogenic Escherichia coli infection | ||||
NetPath Pathway | FSH Signaling Pathway | |||
TCR Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Huntington disease | ||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
Loss of Nlp from mitotic centrosomes | ||||
Recruitment of mitotic centrosome proteins and complexes | ||||
Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
Anchoring of the basal body to the plasma membrane | ||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
Pathogenic Escherichia coli infection | ||||
Mitotic G2-G2/M phases |
References | Top | |||
---|---|---|---|---|
REF 1 | Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.